US FDA declines to approve Outlook Therapeutics' eye disease drug
31/12/2025 21:19
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market. (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce